Accuray to Announce Significant Product News at ASTRO

            Accuray to Announce Significant Product News at ASTRO

2012 ASTRO Meeting Provides Multiple Opportunities to Learn about Accuray's
Leading Radiation Oncology Treatment Solutions

PR Newswire

SUNNYVALE, Calif., Oct. 18, 2012

SUNNYVALE, Calif., Oct. 18, 2012 /PRNewswire/ --Accuray Incorporated (Nasdaq:
ARAY), the premier radiation oncology company, will announce significant
product news at the 54th Annual American Society for Radiation Oncology
(ASTRO) Meeting taking place at the Boston Convention Center. Accuray will
unveil two advanced technology platforms designed to deliver unparalleled,
precise and personalized treatment to the full range of cancer patients. There
will be many opportunities to learn about Accuray's advanced radiation
oncology treatment solutions at the 2012 ASTRO annual meeting, including:

  oNew product unveiling: Join Accuray's President and Chief Executive
    Officer Joshua H. Levine, when he presents the company's two advanced
    technology platforms on Sunday, October 28 at 11:00 a.m. ET in the Accuray
    booth #7101. The presentation will reveal the results of Accuray's
    investment in the development of these next generation technologies, which
    will be on display in the booth. The presentation will review their
    clinical capabilities and the value they bring to both patients and
    physicians within the radiation oncology community.
  oClinical research presentations: Accuray's CyberKnife® Robotic
    Radiosurgery and TomoTherapy® Radiation Therapy Systems will be the
    subject of many clinical presentations and posters. A paper session on
    hypofractionated treatment of prostate cancer that will include three
    talks on CyberKnife prostate SBRT is scheduled for Wednesday, October 30
    from 1:30-3:00 p.m. All presentation dates, times and locations for
    clinical presentations on the CyberKnife and TomoTherapy Systems can be
    found here (
  oIndustry expert theater: Accuray will host a symposium at the ASTRO
    Industry Expert Theater titled, "New Clinical Advancements in the Field of
    Radiosurgery and Radiation Therapy," presented by Mary Ann Stevenson,
    M.D., Ph.D., Radiation Oncologist and Chief, Department of Radiation
    Oncology at Beth Israel Deaconess Medical Center and PD Dr. Florian
    Sterzing, M.D., Consultant Radiation Oncologist at University Clinic of
    Heidelberg on Monday, October 29, 2012 from 12:30 p.m. – 1:30 p.m. ET in
    the Exhibit Hall. Lunch will be served.
  oIn-booth presentations and product demonstrations: At the top of each hour
    while the exhibit hall is open, Accuray will offer in-booth presentations
    and product demonstrations on the clinical advantages of both the
    TomoTherapy and CyberKnife Systems. The  exhibit hall will be open Sunday,
    October 28 – Tuesday, October 30 from 10:00 a.m. – 5:00 p.m. ET each day.
    For those interested in registering for product demonstrations in advance
    please visit:
  oInvestor meeting: Accuray's management will host a breakfast meeting for
    institutional investors and research analysts on Monday, October 29 from
    7:30 a.m. to 9:30 a.m. E.D.T. on Monday, October 29 at the Renaissance
    Boston Waterfront Hotel, 606 Congress Street Boston, in the Pacific
    Ballroom, Salon A-C. The presentation will provide a review of Accuray's
    new technology platforms that will be introduced at ASTRO. A live webcast
    of the presentation will be available online from the investor relations
    section of the company website at Investors and
    analysts planning to attend this meeting are asked to register no later
    than Friday, October 19 from our event website:
  oAdditional ASTRO Activities:

       oAmerican Society of Radiologic Technologists (ASRT) Participation,
         Titanium sponsor: Accuray will be located at table one on the fourth
         floor atrium area of the Boston Marriott Copley Place, Boston MA.
       oThe Society for Radiation Oncology Administrators (SROA)
         participation, Platinum sponsor: Accuray will be located at table
         four found on the first floor the Hyatt Regency, Cambridge, MA.
         Additionally, on Sunday, October 28 at 11:45 a.m. ET Accuray will be
         presenting on our latest product offerings at the SROA table.

Follow the Accuray Twitter handle, @Accuray, for real-time updates from the
ASTRO show floor. To schedule a briefing with an Accuray executive, please
contact Rebecca Phillips, or +1 (408) 242-3831.

About Accuray
Accuray Incorporated (Nasdaq: ARAY), based in Sunnyvale, Calif., is the
premier radiation oncology company that develops, manufactures and sells
personalized innovative treatment solutions that set the standard of care,
with the aim of helping patients live longer, better lives. The Company's
leading edge treatment solutions – the CyberKnife and TomoTherapy Systems –
are designed to deliver radiosurgery, stereotactic body radiation therapy,
intensity modulated radiation therapy, image guided radiation therapy, and
adaptive radiation therapy. To date 642 systems have been installed in leading
hospitals around the world. For more information, please visit

Safe Harbor Statement
Statements made in this press release that are not statements of historical
fact are forward-looking statements and are subject to the "safe harbor"
provisions of the Private Securities Litigation Reform Act of 1995.
Forward-looking statements in this press release relate, but are not limited,
significance of product releases, range of cancer patients, clinical
capabilities of products, clinical research, clinical advantages, quality of
treatments, and the Company's leadership position in radiation oncology
innovation. Forward-looking statements are subject to risks and uncertainties
that could cause actual results to differ materially from expectations,
including risks detailed from time to time under the heading "Risk Factors" in
the company's report on Form 10-K filed on September 10, ^ 2012.
Forward-looking statements speak only as of the date the statements are made
and are based on information available to the Company at the time those
statements are made and/or management's good faith belief as of that time with
respect to future events. The Company assumes no obligation to update
forward-looking statements to reflect actual performance or results, changes
in assumptions or changes in other factors affecting forward-looking
information, except to the extent required by applicable securities laws.
Accordingly, investors should not place undue reliance on any forward-looking

SOURCE Accuray Incorporated

Press spacebar to pause and continue. Press esc to stop.